A Phase 2, Proof-of-Concept, Double-Blind-Randomized, Placebo-Controlled Adaptive Design Trial of Nicotinamide in MCI Due to AD and Mild AD Dementia
December 16, 2016
Joshua Grill, PhD, and Aimee Pierce, MD
UCI campus (1100 Gottschalk Medical Plaza, Irvine; ICTS at Hewitt Hall, Irvine and Newport Diagnostic Center, Newport Beach); UCLA Center for Neurotherapeutics (UCLA Medical Center, 300 Medical Plaza, Westwood Blvd., Los Angeles).
To evaluate whether nicotinamide, also known as vitamin B3 or niacinamide, can reduce phosphorylation or "over-processing" of tau (the protein that accumulates in neurofibrillary tangles) in people with mild cognitive impairment or mild Alzheimer's disease (AD) dementia.
Men and women, aged 50 years and above, and diagnosed with mild cognitive impairment or mild dementia due to Alzheimer's disease
Screening phase (may be up to 60 days) and treatment phase (4 visits over a 12-month period)
You may or may not benefit from participating in this study. The information collected from this study may increase knowledge regarding the treatment of Alzheimer's disease and help people in the future.
Participants are eligible to receive the following compensation in cash during the course of this study:
- Visit 1 completion: $50
- Visit 2 completion: $50
- Visit 3 completion: $50
- Visit 4 completion: $100
The grand total compensation for this study is a maximum of $250 in cash.
Participants will not be reimbursed for travel-related expenses.
Huong Nguyen, Clinical Trials Research Inquiry Coordinator